Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2008

View Archived Issues

Further data on pregabalin efficacy in generalized anxiety disorder reported

Adenosine A3 receptor expression correlated with responses to CF-101 in RA patients

QUATRx reports results from two phase I clinical studies of sobetirome

Novel compounds for cancer treatment disclosed in recent patent literature

Genetic variation in drug transporter ABCB1 is linked to antidepressant efficacy

Sinclair's new herpes simplex treatment registered in the E.U.

Viventia Biotech to consider strategic alternatives

Transtec provides a safe alternative in opioid treatment

Recent Novartis patents describe novel agents for asthma therapy

M's Science initiates European phase II stroke recovery study

Novel treatment options for septic shock imparted in recent Abbott and Takeda patents

FDA accepts BLA filing for Dysport in cervical dystonia

AMAG provides additional information on clinical development program for ferumoxytol

CYT-387 shows encouraging ex vivo results in patients with myeloproliferative disorders

Oncolytics meets criteria to proceed to full enrollment in phase II clinical trial of Reolysin

Millennium and Harvard Medical School sign agreement for protein homeostasis research

Abbott is to invest up to USD 40 million in Ibis Biosciences

Kiadis reports successful completion of phase II clinical trial of Rhitol for GvHD

FDA grants priority review for Schering-Plough's Peg-IFN for stage III melanoma

Preclinical antitumor profile of proteasome inhibitor CEP-18770 reported

AVEO initiates phase Ib clinical trial of AV-951 in metastatic renal cell carcinoma

Pfizer obtains Japanese approval for Revatio in pulmonary hypertension

TargeGen commences clinical trial of TG-101348 in myeloproliferative disease

MediciNova's MN-166 reduces persistent black hole formation in MS

Studies show safety and efficacy of elvucitabine in HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...